{"Clinical Trial ID": "NCT01506609", "Intervention": ["INTERVENTION 1:", "Group 2 Placebo + Carboplatin/Paclitaxel", "On days 1-7 plus the target AUC of carboplatin 6 administered on day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on day 3 of each 21-day cycle.", "INTERVENTION 2:", "Group 2 Veliparib + Carboplatin/Paclitaxel", "V\u00e9liparib 120 mg BID Days 1 to 7 plus Carboplatin 6 target AUC administered on day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on day 3 of each 21-day cycle."], "Eligibility": ["Incorporation criteria:", "A histologically or cytologically confirmed breast cancer that is either locally recurrent or metastatic.", "A local recurrent disease must not be susceptible to surgical resection or radiation with curative intent.", "\u2022 Must have a genetic mutation of noxious breast cancer documented BRCA1 or germinal BRCA2.", "If the human epidermal growth factor receptor (HER2) is positive, subjects should have received and progressed on at least one previous standard HER2 treatment, or the subject should not be eligible for HER2 treatment.", "Assessment criteria (criteria for assessing response in solid tumours) 1.1.", "* Eastern Cooperative Oncology Group (ECOG) performance note of 0-2.", "The subject should have adequate bone marrow, renal and hepatic function.", "The subject should not be pregnant or planning to conceive a child.", "- Exclusion criteria:", "A cancer agent or research agent was received within 21 days prior to C1D1 or radiation therapy within 28 days prior to cycle 1 Day 1.", "More than 2 previous cytotoxic chemotherapy lines.", "A prior treatment of breast cancer with temozolomide, a platinum agent or a polyinhibitor (ADP ribose) Polymerase (PARP).", "A prior taxan therapy for metastatic breast cancer.", "A history or signs of brain metastasis or leptomenal disease.", "A story of uncontrolled convulsive disorders.", "A pre-existing neuropathy, whatever the cause, is greater than Class 1.", "There is a known history of an allergic reaction to cremophor/pallitaxel.", "Significant uncontrolled clinical conditions, active infection, myocardial infarction, stroke or transient ischemic attack, psychiatric illness or social situations that would limit compliance.", "Pregnant or breast-feeding."], "Results": ["Performance measures:", "- Progression-free survival (PFS)", "The PFS is defined as the number of months from the date the participant was randomized to the date of radiographic progression determined by the central imaging centre, or until the date of all causes of death within 63 days of the last tumour assessment if the disease progression was not reached.", "Timeline: Radiographic evaluation every 9 weeks, clinical evaluation every cycle (data collection deadline: 04 March 2016); maximum duration of follow-up of PFS was 34 months.", "Results 1:", "Title of arm/group: Group 2 Placebo + Carboplatin/Paclitaxel", "Description of the arm/group: Placebo IDB Days 1 to 7 plus target of carboplatin AUC 6 administered on day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on day 3 of each 21-day cycle.", "Total number of participants analysed: 98", "Median (95% confidence interval)", "Unit of measure: month 12,3 (9.3-14.5)", "Results 2:", "Title of arm/group: Group 2 Veliparib + Carboplatin/Paclitaxel", "Description of the arm/group: Veliparib 120 mg BID Days 1 to 7 plus Carboplatin 6 target AUC administered on day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on day 3 of each 21-day cycle.", "Total number of participants analysed: 95", "Median (95% confidence interval)", "Unit of measure: month 14.1 (11.5-16.2)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/2 (0.00 per cent)", "ANEMIA 0/2 (0.00 %)", "NEUTROPENIA FEBRILE 0/2 (0.00 %)", "LYMPHADENOPATHY 0/2 (0.00 %)", "NEUTROPENIA 0/2 (0.00 %)", "PANCYTOPENIA 0/2 (0.00 %)", "THROMBOCYTOPENIA 0/2 (0.00 %)", "ATMOSPHERIC FIBRILLATION 0/2 (0.00 %)", "- CARDIAC TAMPONAD 0/2 (0.00 %)", "PERICARDIAL EFFUSION 0/2 (0.00 %)", "TACHYCARDIA 0/2 (0.00 %)", "ABDOMINAL PEACE 0/2 (0.00 %)", "OVERVIEW OF ABDOMINAL PEACE 0/2 (0.00 %)", "Adverse Events 2:", "Total: 0/1 (0.00 per cent)", "ANEMIA 0/1 (0.00 %)", "NEUTROPENIA FEBRILE 0/1 (0.00 %)", "LYMPHADENOPATHY 0/1 (0.00 %)", "NEUTROPENIA 0/1 (0.00 %)", "PANCYTOPENIA 0/1 (0.00 %)", "THROMBOCYTOPENIA 0/1 (0.00 %)", "ATMOSPHERIC FIBRILLATION 0/1 (0.00 %)", "- CARDIAC TAMPONADE 0/1 (0.00 %)", "PERICARDIAL EFFUSION 0/1 (0.00 %)", "TACHYCARDIA 0/1 (0.00 %)", "ABDOMINAL PEACE 0/1 (0.00 %)", "OVERVIEW OF ABDOMINAL PEACE 0/1 (0.00 %)"]}